arrow
M

Michael Offin

memorial sloan kettering cancer center
H指数:39
被引数:7,566

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial

不可切除的III期非小细胞肺癌中,Canakinumab联合化放疗和Durvalumab巩固治疗:CHORUS I/II期试验

2026-09-070
OAAI
Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy

KRAS G12C抑制剂的联合胸部放射治疗安全性特征

2026-03-310
PRE
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy

KRAS突变和共同改变对化疗和免疫治疗的III期非鳞状非小细胞肺癌预后的影响

2026-01-290
PRE
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer

MTAP缺失的临床意义及其与非小细胞肺癌中包括EGFR在内的并发致癌驱动基因改变的重叠情况

2025-11-170
PRE
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

YAP/TEAD抑制剂VT3989在实体瘤中的研究:一项1/2期临床试验

2025-10-190
PRE
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report

更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

2025-06-040
OAAI
Leveraging RNA from DNA Extraction Lysate to Rescue “Insufficient” Samples for More Comprehensive Genomic Profiling in Patients with Scant Tumor Specimens

利用DNA提取裂解液中的RNA来挽救“不足”样本,以实现对肿瘤标本稀少患者更全面的基因组分析

2025-05-150
PRE
First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer

一线免疫治疗与BRAF和MEK抑制剂在BRAF V600E突变型转移性非小细胞肺癌患者中的应用比较

2024-09-010
PRE
Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma

免疫组织化学、新一代测序和荧光原位杂交检测胸膜间皮瘤MTAP丢失的比较

2024-03-015
OAAI
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
2024-02-150
OAAI